Research & Literature

Developments in impulse control behaviours of Parkinson's disease.

Zurowski M, O'Brien JD

Current opinion in neurology 2015; (28(4)):387-92 doi:10.1097/WCO.0000000000000209.

[Current diagnosis and treatment of hyperprolactinemia].

Melgar V, Espinosa E, Sosa E, et al.

Revista medica del Instituto Mexicano del Seguro Social 2016; (54(1)):111-21.

Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma.

Takeno A, Yamamoto M, Okazaki K, et al.

The American journal of case reports 2016; (17()):160-4 doi:10.12659/ajcr.894712.

Prolactinoma and pregnancy: From the wish of conception to lactation.

Maiter D

Annales d'endocrinologie 2016; (77(2)):128-34.

Prolactinoma: A Massive Effect on Bone Mineral Density in a Young Patient.

Sperling S, Bhatt H

Case reports in endocrinology 2016; (2016()):6312621 doi:10.1155/2016/6312621.

Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.

Schwetz V, Librizzi R, Trummer C, et al.

Metabolic brain disease 2017; (32(1)):155-161 doi:10.1007/s11011-016-9882-2.

Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression.

Zaidi HA, Cote DJ, Castlen JP, et al.

World neurosurgery 2017; (97()):2-7 doi:10.1016/j.wneu.2016.09.066.

Significance of surgical management for cystic prolactinoma.

Ogiwara T, Horiuchi T, Nagm A, et al.

Pituitary 2017; (20(2)):225-230 doi:10.1007/s11102-016-0766-6.

How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey.

Karaca Z, Yarman S, Ozbas I, et al.

Journal of endocrinological investigation 2018; (41(1)):129-141 doi:10.1007/s40618-017-0709-8.

Pregnancy and Tumor Outcomes in Women with Prolactinoma.

Araujo B, Belo S, Carvalho D

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2017; (125(10)):642-648 doi:10.1055/s-0043-112861.

Best candidates for dopamine agonist withdrawal in patients with prolactinomas.

Ji MJ, Kim JH, Lee JH, et al.

Pituitary 2017; (20(5)):578-584 doi:10.1007/s11102-017-0820-z.

Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.

Xia MY, Lou XH, Lin SJ, Wu ZB

Endocrine 2018; (59(1)):50-61 doi:10.1007/s12020-017-1444-9.

Analysis of bromocriptine treatment in pregnant pituitary prolactinoma patients.

Lian W, Liu N, Wang RZ, et al.

Clinical and experimental obstetrics & gynecology 2017; (44(2)):203-207.

Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.

Santharam S, Fountas A, Tampourlou M, et al.

Clinical endocrinology 2018; (89(3)):346-353 doi:10.1111/cen.13765.

Spectrum of Pituitary disorders: A retrospective study from Basrah, Iraq.

Mansour AA, Alhamza AHA, Almomin AMSA, et al.

F1000Research 2018; (7()):430 doi:10.12688/f1000research.13632.2.

Falsely decreased ferritin concentrations in two patients with haemophagocytic lymphohistiocytosis: A case report.

Roozen G, Revet I, Raymakers R, Kemperman H

Annals of clinical biochemistry 2019; (56(1)):179-182 doi:10.1177/0004563218793166.

Prolactin-Secreting Lung Adenocarcinoma Metastatic to the Pituitary Mimicking a Prolactinoma: A Case Report.

Yao H, Rui W, Zhang Y, et al.

Neurosurgery 2019; (85(4)):E773-E778 doi:10.1093/neuros/nyy386.

Impulse control disorders in Parkinson's disease: a hard-turning point.

Martinez-Castrillo JC

Journal of neurology, neurosurgery, and psychiatry 2019; (90(1)):2 doi:10.1136/jnnp-2018-319375.

Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old.

Zhao Y, Jin D, Lian W, et al.

Medicine 2019; (98(6)):e14380 doi:10.1097/MD.0000000000014380.

Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients.

Aboelnaga MM, Eladawy EH, Elshafei MM, et al.

Endocrine, metabolic & immune disorders drug targets 2019; (19(4)):511-518 doi:10.2174/1871530319666190219103812.

Interpretation of common endocrine laboratory tests: technical pitfalls, their mechanisms and practical considerations.

Haddad RA, Giacherio D, Barkan AL

Clinical diabetes and endocrinology 2019; (5()):12 doi:10.1186/s40842-019-0086-7.

PTH Immunoassay Interference Due to Human Anti-Mouse Antibodies in a Subject With Obesity With Normal Parathyroid Function.

Laudes M, Frohnert J, Ivanova K, Wandinger KP

The Journal of clinical endocrinology and metabolism 2019; (104(12)):5840-5842 doi:10.1210/jc.2019-01321.

The Role of Surgery in the Management of Prolactinomas.

Donoho DA, Laws ER

Neurosurgery clinics of North America 2019; (30(4)):509-514 doi:10.1016/j.nec.2019.05.010.

Biochemical diagnosis in prolactinomas: some caveats.

Petersenn S

Pituitary 2020; (23(1)):9-15 doi:10.1007/s11102-019-01024-z.

Diagnosis and management of prolactinomas: current challenges.

Petersenn S, Giustina A

Pituitary 2020; (23(1)):1-2 doi:10.1007/s11102-019-01025-y.

Decrease of Proliferative Potential and Vascular Density of Giant Prolactinoma in Patients Treated with Cabergoline.

Astaf'eva L, Shishkina L, Kalinin P, et al.

Asian journal of neurosurgery 2020; (15(2)):385-390 doi:10.4103/ajns.AJNS_16_20.

The Role of Dopamine Agonists in Pituitary Adenomas.

Giraldi EA, Ioachimescu AG

Endocrinology and metabolism clinics of North America 2020; (49(3)):453-474 doi:10.1016/j.ecl.2020.05.006.

Pituitary Microadenoma Treated with Individualized Homeopathic Medicine: A Case Report.

Mathur M

Homeopathy : the journal of the Faculty of Homeopathy 2020; (109(4)):243-247 doi:10.1055/s-0040-1713383.

The risks of medical treatment of prolactinoma.

Castinetti F, Albarel F, Amodru V, et al.

Annales d'endocrinologie 2021; (82(1)):15-19 doi:10.1016/j.ando.2020.12.008.

True hyperprolactinemia in men without visible pituitary adenoma.

Shimon I, Rudman Y, Manisterski Y, et al.

Endocrine 2021; (72(3)):809-813 doi:10.1007/s12020-021-02624-1.

Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas.

Andereggen L, Frey J, Andres RH, et al.

Scientific reports 2021; (11(1)):5122 doi:10.1038/s41598-021-84606-x.

Prevalence of Hyperprolactinemia and Clinically Apparent Prolactinomas in Men Undergoing Fertility Evaluation.

Ambulkar SS, Darves-Bornoz AL, Fantus RJ, et al.

Urology 2022; (159()):114-119 doi:10.1016/j.urology.2021.03.007.

Treatment of hyperprolactinemia: A single-institute experience.

Chen TY, Lee CH, Yang MY, et al.

Journal of the Chinese Medical Association : JCMA 2021; (84(11)):1019-1022 doi:10.1097/JCMA.0000000000000584.

Speed of response to dopaminergic agents in prolactinomas.

Hage C, Salvatori R

Endocrine 2022; (75(3)):883-888 doi:10.1007/s12020-021-02953-1.

A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

Mishra R, Konar SK, Shrivastava A, et al.

Indian journal of endocrinology and metabolism 2021; (25(6)):493-506 doi:10.4103/ijem.ijem_338_21.

Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery.

Bakker LEH, Verstegen MJT, Ghariq E, et al.

Pituitary 2022; (25(4)):587-601 doi:10.1007/s11102-022-01230-2.

Changes in the Options for Management of Prolactin Secreting Pituitary Adenomas.

Iuliano SL, Bi WL, Laws ER

Journal of neurological surgery. Part B, Skull base 2022; (83(Suppl 2)):e49-e53 doi:10.1055/s-0040-1722665.

Recovery of Cranial Nerve Deficits in Patients Presenting with Pituitary Apoplexy: A Case Series.

Alahmari M, Alkherayf F, Lasso A, et al.

Journal of neurological surgery. Part B, Skull base 2022; (83(Suppl 2)):e1-e6 doi:10.1055/s-0040-1722668.

Hook effect in gestational trophoblastic disease: An emergency department case presentation.

Lang J, Byars D, Martin C

Journal of the American College of Emergency Physicians open 2022; (3(5)):e12832 doi:10.1002/emp2.12832.

Natural history of pituitary carcinoma with metastasis to the cervical spine: illustrative case.

Gamboa NT, Wilkerson C, Kundu B, et al.

Journal of neurosurgery. Case lessons 2023; (5(3)).

Operative treatment of cystic prolactinomas: a retrospective study.

Su W, He K, Yang Y, et al.

BMC endocrine disorders 2023; (23(1)):99 doi:10.1186/s12902-023-01343-0.

Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis.

Nagendra L, Dutta D, Mondal S, et al.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2024; (27(1)):101453 doi:10.1016/j.jocd.2023.101453.

A study on the correlations of PRL levels with anxiety, depression, sleep, and self-efficacy in patients with prolactinoma.

Miao X, Fu Z, Luo X, et al.

Frontiers in endocrinology 2024; (15()):1369729 doi:10.3389/fendo.2024.1369729.

Quality of life in Prolactinoma: A systematic review.

Castle-Kirszbaum M, Biermasz N, Kam J, Goldschlager T

Pituitary 2024; (27(3)):239-247 doi:10.1007/s11102-024-01392-1.

Impulse Control Disorders in Southern Iraqi Patients Medicated With Cabergoline for Prolactinoma.

Mohammad MM, Alidrisi HA, Mansour AA

Cureus 2024; (16(4)):e58516 doi:10.7759/cureus.58516.

Characteristics and outcomes of men with erectile dysfunction as the presenting symptom due to a lactotroph adenoma.

Andereggen L, Tortora A, Schubert GA, et al.

Acta neurochirurgica 2024; (166(1)):314 doi:10.1007/s00701-024-06213-9.

Prolactinoma: Navigating the Dual Challenge of Side Effects and Treatment Strategies - A Comprehensive Review.

Yogeeta F, Rauf SA, Devi M, et al.

Annals of medicine and surgery (2012) 2024; (86(8)):4613-4623 doi:10.1097/MS9.0000000000002308.

Usefulness of prolactin levels in predicting the etiology of hyperprolactinemia in a cohort of 770 patients.

Vilar L, Vilar CF, Lyra R, et al.

Archives of endocrinology and metabolism 2024; (68()):e230391 doi:10.20945/2359-4292-2023-0391.

Overview of Hyperprolactinemia: General Approach and Reproductive Health Implications.

Haidenberg-David F, Sidauy-Adissi J, Moscona-Nissan A, et al.

Archives of medical research 2024; (55(8)):103102 doi:10.1016/j.arcmed.2024.103102.

The role of intervention timing and treatment modality in visual recovery following pituitary apoplexy: a systematic review and meta-analysis.

Brown NJ, Patel S, Gendreau J, Abraham ME

Journal of neuro-oncology 2024; (170(3)):469-482 doi:10.1007/s11060-024-04717-z.

Clinical Features and Hormonal Profile of Macroprolactinomas Presenting With the Hook Effect: A Systematic Review.

Mahmoud MM, Haj-Ahmad LM, Sweis NWG, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; (31(2)):215-225 doi:10.1016/j.eprac.2024.11.002.

Disease Activity and Maternal-fetal Outcomes in Pregnant Women With Prolactinoma: A Systematic Review and Meta-analysis.

Bandeira DB, Alves LS, Glezer A, et al.

The Journal of clinical endocrinology and metabolism 2025; (110(4)):e1241-e1251 doi:10.1210/clinem/dgae821.

Correlation between MRI findings of pituitary gland and prolactin level among hyperprolactinemia adult female Saudi patients in rural areas: A retrospective multicentric study.

Alyami N, Alhenaki G, Al Atwah S, et al.

Medicine 2025; (104(2)):e40686 doi:10.1097/MD.0000000000040686.

High-dose Hook Effect in a Case of Giant Prolactinoma Confounded by Acute Kidney Injury.

Lam A, Prosser C, Chik CL

JCEM case reports 2025; (3(8)):luaf136 doi:10.1210/jcemcr/luaf136.

Prolactin impairs erectile function via eNOS suppression independently of testosterone.

Cheng X, Xiao Y, Qiu D, et al.

Toxicology and applied pharmacology 2025; (504()):117532 doi:10.1016/j.taap.2025.117532.

Pituitary apoplexy within a prolactin-secreting macroadenoma in a child: A rare clinical entity with radiological correlation.

Mouhcine Y, Lahjouji O, Ouazzani H, et al.

Radiology case reports 2025; (20(11)):5583-5589 doi:10.1016/j.radcr.2025.07.066.

Management outcomes of prolactinoma: a retrospective study from Southern Iraq.

Alobaidy HF, Alidrisi HA, Reman KA, et al.

Journal of medicine and life 2025; (18(9)):869-877 doi:10.25122/jml-2025-0050.

Hyperprolactinemia alters insulin resistance profiles in overweight males.

Rashed HM, El-Ghlban S, Mahfouz MK, Marie YMA

Endocrine regulations 2025; (59(1)):160-166 doi:10.2478/enr-2025-0018.

Therapeutic challenges of giant invasive cystic macroprolactinoma.

Mekni S, Khiari H, Bouali S, et al.

Endocrinology, diabetes & metabolism case reports 2025; (2025(4)).

Giant Prolactinoma: Challenges in Management.

Sharma S, Acharya M, Sherpa C

AACE endocrinology and diabetes 2025; (12(4)):260-264 doi:10.1016/j.aed.2025.07.004.

Cabergoline and impulse control disorders: Screening patients with pituitary adenomas in an endocrinology clinic.

Lydiatt M, Grissom B, Givens J, et al.

Journal of psychiatric research 2026; (195()):105-112 doi:10.1016/j.jpsychires.2026.01.041.

The Spectrum of Serum Prolactin Levels in Patients with Non-Functioning Sellar Masses: A Retrospective Analysis.

Giri S, Suryadevara V, Ramesh AS, et al.

Neurology India 2026; (74(2)):215-220 doi:10.4103/neurol-india.Neurol-India-D-25-00413.

Prolactinoma diagnosis: Clinical, biochemical, and radiological considerations.

Petersenn S

Best practice & research. Clinical endocrinology & metabolism 2026; (40(2)):102103 doi:10.1016/j.beem.2026.102103.

Impulse control disorders and their relationship with psychopathology in patients treated with cabergoline for hyperprolactinaemia.

Zerbinati L, Cristilli G, Valier B, et al.

Pituitary 2026; (29(3)).

When the test lies: Fatal cryptococcosis and the prozone effect in advanced HIV infection.

Costa M, Rodrigues P, Araújo B, et al.

Diagnostic microbiology and infectious disease 2026; (116(3)):117512 doi:10.1016/j.diagmicrobio.2026.117512.

Disentangling secretory ambiguity and the limitations of classical thresholds in defining prolactinomas.

Harary M, Thapa M, Harper SD, et al.

Pituitary 2026; (29(4)).

Increased impulsivity and higher odds of compulsive shopping among cabergoline-treated patients with prolactinoma: a case-control study.

Daniel KB, Glezer A, de Queiroz NL, et al.

Pituitary 2026; (29(4)).

Pituitary Apoplexy Without Chiasmal Compression Presenting With Radiographic Oculomotor Nerve Compression in a Prolactinoma: A Case Report.

Holz EA, Imran M, Reyes N, Izquierdo-Pretel G

Cureus 2026; (18(6)):e111830 doi:10.7759/cureus.111830.